Is AOD-9604 Legal in Tennessee?

What AOD-9604 Is and Why Its Legal Status Is Complicated

AOD-9604 (Anti-Obesity Drug 9604) is a synthetic peptide fragment derived from amino acids 176 to 191 of human growth hormone (hGH). It was designed specifically to stimulate lipolysis without the insulin-desensitizing effects of full hGH. Despite decades of research, it has never been approved by the FDA as a finished pharmaceutical product.

The Peptide's Origin and Mechanism

AOD-9604 was developed at Monash University in Melbourne, Australia, during the 1990s. Pre-clinical rodent studies showed meaningful reductions in body-fat mass when the compound was administered via subcutaneous injection. The mechanism centers on beta-3 adrenergic receptor stimulation, which accelerates fat breakdown while leaving serum IGF-1 largely unaffected. [1]

Because AOD-9604 does not bind to the full growth-hormone receptor, it avoids the anabolic signaling associated with exogenous hGH, at least in the animal models studied. Human trials were conducted, but results at the doses tested did not meet efficacy thresholds required for FDA approval.

Why "No Controlled Substance" Does Not Mean "Fully Legal"

AOD-9604 is not listed in Schedules I through V of the Controlled Substances Act. [2] That distinction matters, but it does not mean unrestricted access. A compound can be entirely outside DEA scheduling and still require a valid prescription and a licensed pharmacy for legal dispensing. That is exactly where AOD-9604 sits in 2025.

Federal Framework: FDA's Role in Determining Compounding Access

The FDA's authority over peptide compounding comes primarily through two pathways: Section 503A of the Federal Food, Drug, and Cosmetic Act (for traditional compounding pharmacies filling patient-specific prescriptions) and Section 503B (for outsourcing facilities producing larger batch quantities). [3]

The 503A Bulk Substances List

Under 503A, a traditional compounding pharmacy may compound drugs from "bulk drug substances" only if those substances appear on an FDA-approved list, are components of FDA-approved drugs, or meet specific criteria for clinical need. The FDA maintains a running evaluation of nominated bulk substances.

AOD-9604 was nominated and placed under evaluation. In its 2023 guidance action, the FDA effectively moved AOD-9604 to the "Category 2" negative list, meaning it may NOT be compounded by 503A pharmacies because it lacks sufficient evidence of clinical use and raises safety concerns the agency has not resolved. [4] This is the single most consequential regulatory event for AOD-9604 access in the United States, including Tennessee.

What the 2023 FDA Action Actually Said

The FDA's Pharmacy Compounding Advisory Committee reviewed AOD-9604 alongside several other peptides and found that the available human clinical evidence was insufficient to support routine compounding. The committee noted that Phase IIb trials conducted on the peptide (carried out in Australia and submitted to regulatory authorities there) did not produce statistically significant weight loss at the primary endpoint in humans, even though animal data were more promising. [5]

That committee finding does not constitute a criminal prohibition. A 503A pharmacy that compounds AOD-9604 after this determination, however, risks FDA enforcement action, which can include warning letters, injunctions, and product seizures.

503B Outsourcing Facilities: A Narrower Path

Section 503B outsourcing facilities operate under a separate framework and can compound drugs not on the 503A list if the drug is not a "demonstrably difficult to compound" product and other conditions are met. [3] The regulatory picture for AOD-9604 under 503B remains less explicitly settled than under 503A, and individual facilities make their own compliance determinations in consultation with legal counsel.

Patients sometimes encounter clinics or telehealth platforms still offering AOD-9604 through 503B-registered compounders. This is not automatically illegal, but it carries meaningful regulatory risk for the prescriber and pharmacy. The FDA has sent warning letters to compounders offering peptides outside the approved framework, and enforcement activity has increased since 2023. [4]

Tennessee State Law: What the State Does and Does Not Regulate

Tennessee has no statute that specifically names AOD-9604. The state does not maintain its own "approved peptide list" or a parallel prohibition list for peptides. Legal analysis of AOD-9604 availability in Tennessee therefore begins and ends with federal law and the Tennessee Board of Pharmacy's incorporation of federal compounding standards.

Tennessee Board of Pharmacy and Federal Alignment

The Tennessee Board of Pharmacy regulates compounding pharmacies through Title 63, Chapter 10 of the Tennessee Code, and through Board Rule 1140-03-.09. Tennessee compounding regulations generally mirror federal USP standards and defer to FDA guidance on bulk substances. [6] When the FDA places a compound on the Category 2 negative list, Tennessee-licensed 503A pharmacies are effectively bound by that determination, because a pharmacy that ignores it risks losing its license for violating the federal standard incorporated by state rule.

Tennessee Medical Practice Act Considerations

A Tennessee-licensed physician retains broad prescribing authority under the Tennessee Medical Practice Act (Tenn. Code Ann. § 63-6-201 et seq.). The Act requires that any prescription be issued within a valid patient-physician relationship and for a legitimate medical purpose. [7] Prescribing AOD-9604 for weight loss when the FDA has flagged it as lacking sufficient evidence of safety and efficacy for compounding is a professional-risk decision. A physician could face Board of Medical Examiners scrutiny if a patient is harmed and the record does not document a clear clinical rationale.

No Tennessee-Specific Criminal Prohibition

To be direct: no Tennessee statute makes possession or personal use of AOD-9604 a crime, provided the individual obtained it with a valid prescription from a licensed practitioner. Possession without a prescription could theoretically be prosecuted under Tennessee's legend-drug statute (Tenn. Code Ann. § 53-10-104), which prohibits possession of prescription drugs without a valid prescription, but AOD-9604 prosecutions under that statute are not documented in publicly available case law as of this writing.

How to Get AOD-9604 in Tennessee Legally

Getting AOD-9604 legally in Tennessee in 2025 requires navigating three gatekeepers: a licensed prescriber, a compliant pharmacy, and documentation that supports the prescription's legitimacy. Each step has narrowed since 2023.

Step 1: Establish Care with a Qualified Prescriber

The prescriber must be licensed in Tennessee and must conduct a legitimate clinical evaluation. Telehealth consultations satisfy this requirement when the platform is compliant with Tennessee telehealth law (Tenn. Code Ann. § 63-1-155), which requires that the provider be licensed in Tennessee and that the standard of care be equivalent to in-person care. [7]

A provider who writes an AOD-9604 prescription should document:

• The patient's current BMI and weight history
• Prior weight-loss interventions attempted, including FDA-approved agents
• A specific clinical rationale for choosing AOD-9604 over approved alternatives
• Informed consent noting that AOD-9604 is not FDA-approved

Step 2: Identify a Compliant Compounding Pharmacy

After the 2023 FDA action, 503A pharmacies in Tennessee should not be compounding AOD-9604. A patient or provider sourcing it from a 503A compounder after that determination is working outside the intended regulatory framework.

503B outsourcing facilities are a different question. A Tennessee provider may write a prescription fulfilled by a 503B facility registered with the FDA, provided that facility has determined AOD-9604 is within its compliant scope. The provider should request documentation of the facility's compliance review before prescribing.

Purchasing AOD-9604 from overseas websites, research-chemical suppliers, or unregulated domestic vendors carries serious risk. These products are not manufactured under Current Good Manufacturing Practice (cGMP) standards, may contain incorrect concentrations or contaminants, and leave the buyer with no legal recourse if harmed. [4]

Step 3: Consider FDA-Approved Alternatives First

Regulatory complexity around AOD-9604 makes it worth comparing to approved agents:

• Semaglutide 2.4 mg (Wegovy): In STEP-1 (N=1,961), produced 14.9% mean body-weight reduction at 68 weeks versus 2.4% with placebo (P<0.001). [8]
• Tirzepatide 15 mg (Zepbound): In SURMOUNT-1 (N=2,539), produced 20.9% mean weight reduction at 72 weeks versus 3.1% with placebo (P<0.001). [9]

Neither AOD-9604 trial produced a comparable human weight-loss signal at an approvable endpoint. A prescriber offering AOD-9604 without first documenting consideration of these agents faces a harder compliance argument if questioned.

Clinical Evidence: What the Research Actually Shows

Understanding the evidence base matters because regulatory decisions follow clinical data. AOD-9604 has a real, if limited, published record.

Animal Data

Rodent models published as early as 1996 showed that AOD-9604 reduced body fat in obese mice without affecting blood glucose or IGF-1 levels. [1] These findings were replicated in several pre-clinical studies and formed the basis for human trials.

Human Phase II and Phase IIb Trials

Human trials were conducted primarily in Australia under the sponsorship of Monash University and later Metabolic Pharmaceuticals. A 12-week Phase II dose-ranging study showed modest reductions in body fat at higher doses (1 mg/day oral formulation) compared to placebo, but the effect size was small. [5]

Phase IIb trials extending to 24 weeks did not meet their primary endpoint for statistically significant weight loss in the intent-to-treat population. These results led Metabolic Pharmaceuticals to halt further development of the oral formulation. Subcutaneous formulations were studied separately but did not advance to Phase III trials in the United States.

Cartilage and Joint Research

A separate line of research explored AOD-9604's potential in osteoarthritis. In vitro and animal studies suggested the peptide may stimulate cartilage repair through mechanisms unrelated to its lipolytic action. [10] No completed Phase III human trial has validated this application, and no FDA review of a finished-drug application for AOD-9604 in osteoarthritis exists as of mid-2025.

What the Evidence Gap Means for Tennessee Patients

The FDA's Category 2 determination was not punitive. It reflected a genuine evidence gap: the human trials conducted were not powered or designed to meet the modern FDA standard for efficacy, and the safety database for long-term human use at subcutaneous doses is thin. Tennessee patients considering AOD-9604 should weigh this gap seriously and discuss it openly with their provider.

Risks of Obtaining AOD-9604 Outside a Medical Supervision Framework

Patients who obtain AOD-9604 from unregulated sources face risks that go beyond legal exposure.

Product Quality and Contamination

Research-chemical vendors selling AOD-9604 "for research use only" are not manufacturing under cGMP standards required for human pharmaceutical use. [4] Independent laboratory analyses of peptide products purchased from gray-market vendors have found incorrect peptide sequences, bacterial endotoxin contamination, and concentrations that vary by as much as 40% from the label claim. Injecting such a product carries infection risk, including injection-site abscesses and systemic bacteremia.

Legal Exposure for Patients

A Tennessee resident who purchases AOD-9604 without a prescription may technically violate the state's legend-drug statute. Enforcement is rare, but the risk is not zero, and the greater practical risk is medical: no physician-patient relationship means no monitoring, no dose adjustments, and no recourse if adverse effects occur.

Legal Exposure for Providers

A Tennessee physician who prescribes AOD-9604 through a non-compliant channel, without documented clinical rationale, or while directing patients to unregulated vendors could face Tennessee Board of Medical Examiners discipline for unprofessional conduct under Tenn. Code Ann. § 63-6-214, up to and including license revocation.

Regulatory Outlook: Could AOD-9604 Status Change?

The FDA bulk-substance evaluation process is ongoing. A compound placed on the Category 2 list is not permanently banned. A manufacturer could submit a New Drug Application (NDA) with sufficient clinical evidence to obtain FDA approval, at which point the calculus for compounding changes. Alternatively, the Pharmacy Compounding Advisory Committee could revisit its evaluation if new human clinical data emerge.

As of July 2025, no active NDA for AOD-9604 appears in the FDA's publicly searchable drug database. [11] No Phase III U.S. Trial is listed as actively recruiting on ClinicalTrials.gov for AOD-9604 as a weight-loss or osteoarthritis intervention at the time of this article's review.

The Endocrine Society's 2023 clinical practice guideline on obesity pharmacotherapy does not list AOD-9604 among recommended or investigational agents, reflecting its current evidence status. [12]

Practical Summary for Tennessee Patients and Providers

AOD-9604 sits in a zone that is not controlled, not approved, and not straightforwardly accessible after the 2023 FDA compounding action. Tennessee adds no separate state-law clarity. The path to legal access, if a clinician determines it is clinically appropriate, runs through a 503B-registered outsourcing facility and a prescriber willing to document a defensible clinical rationale.

Patients in Tennessee interested in weight management have access to FDA-approved GLP-1 receptor agonists and dual GIP/GLP-1 agonists through telehealth and traditional office-based care, and those agents carry a far stronger evidence base and clearer legal standing.

Any Tennessee provider or patient considering AOD-9604 should consult with a healthcare attorney familiar with pharmaceutical regulatory law and confirm the compounding facility's current compliance status before proceeding. The regulatory environment has shifted materially since 2022, and clinics or websites that have not updated their protocols may be operating on outdated legal assumptions.

The Tennessee Department of Health maintains a licensee lookup at health.tn.gov that allows patients to verify a prescriber's current license status. Using a licensed, in-state provider is the minimum threshold for any prescription involving a compound in this regulatory position.